
|Videos|March 23, 2016
Jason R. Gotlib on JAK Inhibitors for the Treatment of Myelofibrosis
Author(s)Jason R. Gotlib
Jason R. Gotlib discusses JAK inhibitors for the treatment of patients with myelofibrosis.
Advertisement
Jason R. Gotlib, associate professor of Medicine (Hematology) at Stanford University Medical Center, discusses JAK inhibitors for the treatment of patients with myelofibrosis.
Gotlib discusses whether next-generation JAK inhibitors should be used after resistance to Jakafi (ruxolitinib) or in the frontline setting. Gotlib also provided an overview of drugs that are being studied in combination with these agents.
Gotlib is a
Advertisement
Advertisement
Advertisement
Trending on CURE
1
All FDA Oncology Approvals From September 2025
2
FDA Approves Enoby and Xtrenbo Biosimilars for Bone Health and Cancer Care
3
Pelvic Physical Therapy After Cancer Restores Intimacy, Wellness
4
September Blood Cancer Updates: What Patients Should Know
5